Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
How Phase 3 CALIBRATE data reshapes BridgeBio Pharma, Inc.’s rare disease strategy (NASDAQ: BBIO)
Can BridgeBio Pharma, Inc.’s CALIBRATE data turn encaleret into a rare endocrine breakthrough? Explore strategy, risks, and market impact.
CapsCanada rebrands as Lyfe Group to unify capsule manufacturing and drug delivery operations
Capsule makers face scale, compliance, and formulation pressure. Lyfe Group’s rebrand shows how CapsCanada wants to compete globally.
Is biomarker-driven approval the breakthrough ALS drug development has been waiting for?
Can neurofilament light fast-track ALS drug approvals? Explore how Clene Inc.’s FDA signal could reshape timelines, risk, and competition.
How skeletal endpoints are becoming central to Gaucher disease innovation strategies
FLT201 data shifts focus to skeletal endpoints in Gaucher disease. Discover what this means for gene therapy strategy and market competition.
Avacta Group (AIM: AVCT) delivers preCISION payload data that challenges Enhertu and Datroway tumor selectivity at Science Day 2026
Avacta is no longer pitching a platform. It is benchmarking preCISION directly against Enhertu and Datroway, and the tumor selectivity numbers matter.
MingMed Biotechnology’s oral QA102 Phase II data puts intermediate dry AMD in the spotlight
Dry AMD has injection options late, but few answers earlier. MingMed’s QA102 asks whether oral therapy can change that risk window.
Citius Oncology (CTOR) stock in focus as $36.5m financing targets LYMPHIR commercialization
Citius Oncology has capital and an approved CTCL drug. The harder question is whether LYMPHIR can turn niche oncology promise into revenue.
Tango Therapeutics (NASDAQ: TNGX) jumps 11% into May 11 earnings and pivotal pancreatic cancer data
Tango Therapeutics is up 22-fold from $1.04 in twelve months. The May 11 earnings print decides whether vopimetostat justifies the run or breaks it.
Mirum Pharmaceuticals (NASDAQ: MIRM) jumps 13% after VISTAS Phase 2b PSC win
Two Phase 2b wins in seven days. A pre-NDA meeting this summer. Mirum is starting to look less like a single-product rare disease story.
Why ESR1 mutation targeting is critical in metastatic breast cancer treatment
FDA approves VEPPANU. Discover why ESR1 mutation targeting is reshaping metastatic breast cancer treatment and what it means next.